Peptide revolution: Genomics, proteomics and therapeutics

BioTechniques

Volumn 34, Issue 3, 2003, Pages 594-599

  Sawyer, T K ^a   Chorev, M ^b  

^a ARIAD PHARMACEUTICALS INC   (United States)

^b HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; PEPTIDE;

DRUG RESEARCH; GENOMICS; HUMAN; MEDICAL RESEARCH; NONHUMAN; NOTE; PEPTIDE SYNTHESIS; PROTEIN MODIFICATION; PROTEIN STRUCTURE; PROTEOMICS;

EID: 0037335029     PISSN: 07366205     EISSN: None     Source Type: Journal    
DOI: 10.2144/03343dd01     Document Type: Note

References (100)

1. Ahn, J.A., N.A. Boyle, M.T. MacDonald, and K.D. Janda. 2002. Peptidomimetics and peptide backbone modifications. Mini Rev. Med. Chem. 2:463-473.
2. Al-Obeidi, F.A., V.J. Hruby, and T.K. Sawyer. 1998. Peptide and peptidomimetic libraries: molecular diversity and drug design. Mol. Biotechnol. 9:205-223.
3. Bursavich, M.G. and D.H. Rich. 2002. Designing non-peptide peptidomimetics in the 21st century: inhibitors targeting conformational ensembles. J. Med. Chem. 31:541-558.
4. Chorev, M. and M. Goodman. 1995. Recent developments in retro pepides and proteins - an ongoing topochemical exploration. Trends Biotechnol. 13:438-445.
5. Eguchi, M. and M. Kahn. 2002. Design, synthesis, and application of peptide secondary structure mimetics. Mini Rev. Med. Chem. 2:447-462.
6. Fairlie, D.P., G. Abbenante, and D.R. March. 1995. Macrocyclic peptidomimetics: forcing peptides into bioactive conformations. Curr. Med. Chem. 2:654-686.
7. Freidinger, R.M. 1999. Nonpeptidic ligands for peptide and protein receptors. Curr. Opin. Chem. Biol. 3:395-406.
8. Goodman, M. and S. Ro. 1994. Peptidomimetics for drug design, p. 803-861. In M.E. Wolff (Ed.), Medicinal Chemistry and Drug Design. vol. I. Principles of Drug Discovery. 5th ed. John Wiley & Sons, New York.
9. Houghten, R.A. 2000. Parallel array and mixture-based synthetic combinatorial chemistry: tools for the next millennium. Annu. Rev. Pharmacol. Toxicol. 40:273-282.
10. Hruby, V.J., F.A. Al-Obeidi, and W. Kazmierski. 1990. Emerging approaches in the molecular design of receptor-selective peptide ligands. Biochem. J. 268:249-262.
11. Hruby, V.J. 2002. Designing peptide receptor agonists and antagonists. Nat. Rev. Drug Discov. 1:847-858.
12. Lam, K.S. and Renil, M. 2002. From combinatorial chemistry to chemical microarray. Curr. Opin. Chem. Biol. 6:353-358.
13. Marshall, G.R. 1993. A hierarchial approach to peptidomimetic design. Tetrahedron 49:3547-3558.
14. Olson, G.L., D.R. Bolin, N.P. Bonner, M. Bos, C.M. Cook, D.C. Fry, B.J. Graves, et al. 1993. Concepts and progress in the development of peptide mimetics. J. Med. Chem. 36:3039-3049.
15. Rich, D.H. 2002. Discovery of nonpeptide, peptidomimetic peptidase inhibitors that target alternate enzyme active site conformations. Biopolymers 66:115-125.
16. Ripka, A.S. and D.H. Rich. 1998. Peptidomimetic design. Curr. Opin. Chem. Biol. 2:441-452.
17. Sawyer, T.K. 1999. Peptidomimetic and nonpeptide drug discovery: chemical nature and biological targets, p. 81-114. In R. Reid (Ed.), Drugs and the Pharmaceutical Sciences. vol. 101. Marcel Dekker, New York.
18. Sawyer, T.K. 1997. Peptidomimetic and nonpeptide drug discovery: impact of structure-based design, p. 559-634. In P. Veerapandian (Ed.), Structure-Based Drug Design: Diseases, Targets, Techniques and Developments. Marcel Dekker, New York.
19. Sundaram, R., N.K. Dakappagari, and P.T. Kaumaya. 2002. Synthetic peptides as cancer vaccines. Biopolymers 66:200-216.
20. Jackson, D.C., A.W. Purcell, C.J. Fitzmaurice, W. Zeng, and D.N. Hart. 2002. The central role played by peptides in the immune response and the design of peptide-based vaccines against infectious diseases and cancer. Curr. Drug Targets 3:175-196.
21. Burton, P.S., R.A. Conradi, N.F. Ho, A.R. Hilgers, and R.T. Borchardt. 1996. How structural features influence the biomembrane permeability of peptides. J. Pharm. Sci. 85:1336-1340.
22. LaVan, D.A., D.M. Lynn, and R. Langer. 2002. Moving smaller in drug discovery and delivery. Nat. Rev. Drug Discov. 1:77-84.
23. Bernkop-Schnurch, A. and G. Walker. 2001. Multifunctional matrices for oral peptide delivery. Crit. Rev. Ther. Drug Carrier Syst. 18:459-501.
24. Craik, D.J., S. Simonsen, and N.L. Daly. 2002. The cyclotides: novel macrocyclic peptides as scaffolds in drug design. Curr. Opin. Drug Discov. Develop. 5:251-260.
25. Micklatcher, C. and J. Chmielewski. 1999. Helical peptide and protein design. Curr. Opin. Chem. Biol. 3:724-729.
26. Liu, L.P. and C.M. Deber. 1998. Guidelines for membrane proteins engineering derived from de novo designed model peptides. Biopolymers 47:41-62.
27. Annis, I., B. Hargittal, and G. Barany. 1997. Disulfide bone formation in peptides. Methods Enzymol. 289:198-221.
28. Dawson, P.E. and S.B. Kent. 2000. Synthesis of native proteins by chemical ligation. Annu. Rev. Biochem. 69:923-960.
29. Sakakibara, S. 1995. Synthesis of large peptides in solution. Biopolymers 37:17-28.
30. Sadler, K. and J.P. Tam. 2002. Peptide dendrimers: applications and synthesis. J. Biotechnol. 90:195-229.
31. Cheng, R.P., S.H. Gellman, and W.F. DeGrado. 2001. β-peptides: from structure to function. Chem. Rev. 101:3219-3232.
32. Steer, D.L., R.A. Lew, P. Perlmutter, A.I. Smith, and M.I. Aguilar. 2002. β-amino acids: versatile peptidomimetics. Curr. Med. Chem. 9:811-822.
33. Figliozzi, G.M., R. Goldsmith, S.C. Ng, S.C. Banville, and R.N. Zuckermann. 1996. Synthesis of N-substituted glycine peptoid libraries. Methods Enzymol. 267:437-447.
34. Gadek, T.R. and J.B. Nicholas. 2003. Small molecule antagonists of proteins. Biochem. Pharmacol. 76:1-8.
35. Hirschmann, R., P.A. Sprengeler, T. Kawasaki, J.W. Leahy, W.C. Shakespeare, and A.B. Smith III. 1992. The first design and synthesis of a steroidal peptidomimetic. The potential value of peptidomimetics in elucidating the bioactive conformation of peptide ligands. J. Amer. Chem. Soc. 114:9699-9701.
36. Hirschmann, R., K.C. Nicolaou, S. Pietranico, J. Salvino, E.M. Leahy, P.A. Sprengeler, G. Furst, et al. 1992. Nonpeptidal peptidomimetics with β-P-D-glucose scaffolding. A partial somatostatin agonist bearing close structural relationship to a potent, selective substance P antagonist. J. Amer. Chem. Soc. 114:9217-9218.
37. Kempf, D. and H.L. Sham. 1996. HIV protease inhibitors. Curr. Pharm. Design 2:225-246.
38. Qian, Y., S.M. Sebti, and A.D. Hamilton. 1997. Farnesyltranserase as a target for anticancer drug design. Biopolymers (Pept. Sci.) 43:25-41.
39. Roberts, N.A., J.A. Martin, D. Kinchington, A.V. Broadhurst, J.C. Craig, I.B. Duncan, S.A. Galpin, et al. 1990. Rational design of peptide-based HIV proteinase inhibitors. Science 248:358-361.
40. Rohrer, S.P., E.T. Birzin, R.T. Mosley, S.C. Berk, S.M. Hutchins, D.-M. Shen, Y. Xiong, et al. 1998. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 282:737-740.
41. Sawyer, T.K., R.S. Bohacek, D.C. Dalgarno, C.J. Eyermann, N. Kawahata, C.A. Metcalf, et al. 2002. Src homology-2 inhibitors: peptidomimetic and nonpeptide. Mini Rev. Med. Chem. 2:475-488.
42. Sebhat, I.K., M.J. Martin, Z. Ye, K. Barakat, R.T. Mosley, D.B. Johnston, R. Bakishi, et al. 2002. Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium-3-ylcarbonyl]-(1R)-1 (4-chlorobenzyl)-2-[4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-2- oxoethylamine (1), a potent, selective, melanocortin subtype-3 receptor agonist. J. Med. Chem. 45:489-4593.
43. Smith, A.B., S.D. Knight, P.A. Sprengler, and R. Hirschmann. 1996. The design and synthesis of 2,5-linked pyrrolinones: a potential non-peptide peptidomimetic scaffold. Bioorg. Med. Chem. 4:1021-1034.
44. Shakespeare, W.C., M. Yang, R. Bohacek, F. Cerasoli, K. Stebbins, R. Sundaramoorthi, et al. 2000. Structure-based design of an osteoclast-selective, nonpeptide Src homology-2 inhibitor with in vivo antiresorptive activity. Proc. Natl. Acad. Sci. USA 15:9373-9378.
45. International Human Genome Sequencing Consortium. 2001. Initial sequencing and analysis of the human genome. Nature 409:860-921.
46. Venter, C., M.D. Adams, E.W. Myers, P.W. Li, R.J. Mural, G.G. Sutton, H.O. Smith, et al. The sequence of the human genome. Science 291:1304-1351
47. Dalgarno, D., C. Metcalf, W. Shakespeare, and T.K. Sawyer. 2000. Signal transduction drug discovery: targets, mechanisms, and structure-based design. Curr. Opin. Drug Disc. Dev. 3:549-564.
48. Cooper, J.B. 2002. Aspartic proteinases in disease: a structural perspective. Curr. Drug Targets 3:155-73.
49. Blundell, T.L., H. Jhotti, and C. Abell. 2002. High-throughput crystallography for lead discovery in drug design. Nat. Rev. Drug Discov. 1:45-54.
50. Diercks, T., M. Coles, and H. Kessler. 2001. Applications of NMR in drug discovery. Curr. Opin. Chem. Biol. 5:285-291.
51. Hajduk, P.J., R.P. Meadows, and S.W. Fesik. 1999. NMR-based screening in drug discovery. Q. Rev. Biophys. 32:211-240.
52. Nienaber, V.L., P.L. Richardson, V. Klighofer, J.J. Bouska, V.L. Giranda, and J. Green. 2001. Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat. Biotechnol. 18:1105-1108.
53. Karle, I.L. 1996. Flexibility in peptide molecules and restraints imposed by hydrogen bonds, the Aib residue, and core inserts. Biopolymers. 40:157-180.
54. Antel, J. 1999. Integration of combinatorial chemistry and structure-based drug design. Curr. Opin. Drug Disc. Dev. 2:224-233.
55. Bohacek, R. and C. McMartin. 1997. Modem computational chemistry and drug discovery: structure-generating programs. Curr. Opin. Chem. Biol. 1:157-161.
56. Bohm, H.-J. and M. Stahl. 2000. Structure-based library design: molecular modeling merges with combinatorial chemistry. Curr. Opin. Chem. Biol. 4:283-286.
57. Davies, T.G., J.R.H. Tame, and R.E. Hubbard. 2001. Generating consistent sets of thermodynamic and structural data for analysis of protein-ligand interactions. Perspect. Drug Disc. Design. 20:29-42.
58. Joseph-McCarthy, D. 1999. Computational approaches to structure-based drug design. Pharmocol. Ther. 84:179-191.
59. Klebe, G. 2000. Recent developments in structure-based drug design. J. Mol. Med. 78:269-281.
60. Langer, T. and R.D. Hoffmann. 2001. Virtual screening: an effective tool for lead structure discovery. Curr. Pharm. Des. 7:509-527.
61. Li, J. and B. Robson. 2000. Bioinformatics and computational chemistry in molecular design: recent advances and their applications. Drugs Pharm. Sci. (Peptide and Protein Drug Analysis) 101:285-307.
62. Norin, M. and M. Sundstrom. 2001. Protein models in drug discovery. Curr. Opin. Drug Discov. Develop. 4:284-290.
63. Mason, J.S., A.C. Good, and E.J. Martin. 2001. 3-D pharmacophores in drug discovery. Curr. Pharm. Des. 7:567-597.
64. Muege, I. and Y.C. Martin. 1999. A general and fast scoring function for protein-ligand interactions: a simplified potential approach. J. Med. Chem. 42:791-804.
65. Murcko, M.A., P.R. Caron, and P.S. Charifson. 1999. Structure-based drug design. Annu. Rep. Med. Chem. 34:297-306.
66. Roche, O., R. Kiyama, and C.L. Brooks III. 2001. Ligand-protein database: linking protein-ligand complex structures to binding data. J. Med. Chem. 44:3592-3598.
67. Martin, A.B. and P.G. Schultz. 1999. Opportunities and the interface of chemistry and biology. Trends Cell Biol. 9:M24-28.
68. Sisido, M. and T. Hohsaka. 2001. Introduction of specialty functions by the position-specific incorporation of non-natural amino acids into proteins through four-base codon/anticodon pairs. Appl. Microbiol. Biotechnol. 57:274-281.
69. Caron, P.R., M.D. Mullican, R.D. Marshal, K.P. Wilson, M.S. Su, and M.A. Murcko. 2001. Chemogenomic approaches in drug discovery. Curr. Opin. Chem. Biol. 5:464-270.
70. Zambrowicz, B.P. and A.T. Sands. 2003. Knockout model the 100 best-selling drugs - will they model the next 100? Nat. Drug Discov. 2:38-51.
71. Olsson, T. and T.I. Oprea. 2001. Cheminformatics: a tool for decision-makers in drug discovery. Curr. Opin. Drug Disc. Dev. 4:308-313.
72. Lipinski, C.A., F. Lombardo, B.W. Dominy, and P.J. Feeney. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:3-26.
73. Ulrich, R. and S.H. Friend. 2002. Toxicogenomics and drug discovery: will new technologies help us produce better drugs? Nat. Rev. Drug Discov. 1:84-88.
74. Van de Waterbeemd, H., D.A. Smith, K. Beaumont, and D.K. Walker. 2001. Property-based design: optimization of drug absorption and pharmacokinetics. J. Med. Chem. 44:1313-1333.
75. Marshall, G.R. 2001. Peptide interactions with G-protein coupled receptors. Biopolymers. 60:246-277.
76. Filipek, S., D.C. Teller, K. Palczewski, and R. Stenkamp. 2003. The crystallographic model of rhodopsin and its use in studies of other G protein-coupled receptors. Annu. Rev. Biophys. Biomol. Struct. Feb. 5 Published online.
77. Weismann, C. and A.M. De Vos. 1999. Putting two and two together: crystal structure of the FGF-receptor complex. Structure 7:R251-R255.
78. Ogiso, H., R. Ishitani, O. Nureki, S. Fukai, M. Yamanaka, J.H. Kim, K. Saito, A. Sakamoto, et al. 2002. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110:775-787.
79. 3. Science 296:151-155.
80. Gadek, T.R., D.J. Burdick, R.S. McDowell, M.S. Stanley, J.C. Marsters, Jr., K.J. Paris, et al. 2002. Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory eptitope to a small molecule. Science 295:1086-1089.
81. Szakonyi, G., J.M. Guthridge, D. Li, K. Young, V.M. Holers, and X.S Chen. 2001. Structure of complement receptor 2 in complex with its C3d ligand. Science 292:1725-1728.
82. Chow, D.-C., H.-I. He, A.L Snow, S. Rose-John, and K.C. Garcia. 2001. Structure of an extracellular gp130 cytokine receptor signaling complex. Science 291:2150-2155.
83. Reinherz, E.L., K. Tan, L. Tang, P. Kern, J.-H. Liu, R.E. Hussey, et al. 1999. The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science 286:1913-1921.
84. Roggo, S. 2002. Inhibition of BACE, a promising approach to Alzheimer's disease therapy. Curr. Topics Med. Chem. 2:359-370.
85. Bowman, M.J. and J. Chmielewski. 2002. Novel strategies for targeting the dimerization interface of HIV protease with cross-linked interfacial peptides. Biopolymers 66:126-133.
86. Yamashita, D.S. and R.A. Dodds. 2000. Cathepsin K and the design of inhibitors of cathepsin K. Curr. Pharm. Design. 6:1-24.
87. Concha, N.O. and S.S. Abdel-Meguid. 2002. Controlling apoptosis by inhibition of caspases. Curr. Med. Chem. 9:73-726.
88. Quan, M.L. and R.R. Wexler. 2001. The design and synthesis of noncovalent Factor Xa inhibitors. Curr. Topics Med. Chem. 1:137-149.
89. Maiganan, S. and V. Mikol. 2001. The use of 3D structural data in the design of specific Factor Xa inhibitors. Curr. Topics Med. Chem. 1:161-174.
90. Skiles, J.W., N.C. Gonnella, and A.Y. Jeng. 2001. The design, structure and therapeutic application of matrix metalloproteinase inhibitors. Curr. Med. Chem. 8:425-474.
91. Lauer-Fields, J.L., D. Juska, and G.B. Fields. 2002. Matrix metalloproteinases and collogen catabolism. Biopolymers. 66:19-32.
92. Singh, S.B. and R.B. Lingham. 2002. Current progress on famesyl protein transferase inhibitors. Curr. Opin. Drug Discov. Develop. 5:225-244.
93. Songyang, Z. and LC Cantley. 1995. Recognition and specificity in protein tyrosine kinase-mediated signaling. Trends Biochem. Sci. 20:471-475.
94. Alfaro-Lopez, J., W. Yuan, B.C. Phan, J. Kamath, Q. Lou, K.S. Lam, and V.J. Hruby. 1998. Discovery of a novel series of potent and selective substrate-based inhibitors of pp60c-src protein tyrosine kinase: conformational and topographical constraints in peptide design. J. Med. Chem. 18:2252-2260.
95. Burke, Jr., T.R., Z.J. Yao, D.C. Liu, J. Voigt, and Y. Gao. 2001. Phosphoryltyrosyl mimetics in the design of peptide-based signal transduction inhibitors. Biopolymers. 60:32-44.
96. Zhang, Y.Z. 2001. Protein tyrosine phosphatases: prospects for therapeutics. Curr. Opin. Chem. Biol. 5:416-423.
97. Huang Z. 2000. Bcl-2 family proteins as targets for anticancer drug design. Oncogene 19:6627-6631.
98. Blundell, T.L. D.F. Burke, D. Chirgadze, V. Dhanaraj, M. Hyvonen, C.A. Innis, E. Parisini, L. Pellegrini, et al. 2000. Protein-protein interactions in receptor activation and intracellular signaling. Biol. Chem. 381:955-959.
99. DeLano, W.L., M.H. Ultsch, A.M. deVos, and J.A. Wells. 2000. Convergent solutions to binding at a protein-protein interface. Science 287:1279-1283.
100. Guo, Z., D. Zhou, and P.G. Schultz. 2000. Designing small-molecule switches for protein-protein interactions. Science 288:2042-2045.